WHI-P154 NEW
| Price | $56 | $88 | $185 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: WHI-P154 | CAS No.: 211555-04-3 |
| Purity: 99.6% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | WHI-P154 |
| Description | WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor. |
| Cell Research | Cells are seeded into a 96-well plate at a density of 2.5×104 cells/well and incubated for 36 h at 37 ℃ before drug exposure. On the day of treatment, culture medium is carefully aspirated from the wells and replaced with fresh medium containing the quinazoline compounds WHI-P154 at concentrations ranging from 0.1 μM to 250 μM. Triplicate wells are used for each treatment. The cells are incubated with the compound for 24hours to 36hours at 37 ℃ in a humidified 5% CO2 atmosphere. To each well, 10 μL of MTT (final concentration, 0.5 mg/mL) is added, and the plate are incubated at 37 ℃ for 4 h. Than solubilized overnight at 37 ℃ in a solution containing 10% SDS in 0.01 M HCL. The absorbance of each well is measured in a microplate reader at 570 nm.(Only for Reference) |
| Kinase Assay | Kinase assays: WHI-P154 is tested in kinase assays. The panel of kinases is selected to broadly cover the kinome, providing a good approximation of specificity. For all kinases, recombinant rat (IKKβ) or human (all others), full-length or GST-kinase domain fusion proteins, are used. WHI-P154 is inactive (concentration that inhibits response by 50% [IC50] > 30 μM) for the following kinases: AKT, AuroraA, cdk2, cdk6, CHK1, FGFR1, GSK3b, IKKb, IKKi, INSR, MAPK1, MAPKAP-K2, MASK, MET, PAK4, PDK1, PKCb, ROCK1, TaoK3, TrkA. |
| In vitro | The in vitro anti-glioblastoma activity of WHI-P154 was amplified > 200-fold and was selective by binding to recombinant human-derived epidermal growth factor. WHI-P154 inhibited STAT1 activation, iNOS expression and NO production in macrophages in vitro. WHI-P154 was shown to inhibit other common kinases, including EGFR, Src, Abl, VEGFR, MAPK and PI3-K, and induced apoptosis in human glioblastoma cell lines.WHI-P154 inhibited the adhesion and migration of glioblastoma cells in the ECM. WHI-P154 was significantly cytotoxic to human malignant glioma cell lines U373 and U87, causing apoptotic cell death at micromolar concentrations. |
| In vivo | The in vitro anti-glioblastoma activity of WHI-P154 was amplified > 200-fold and was selective by binding to recombinant human-derived epidermal growth factor. WHI-P154 inhibited STAT1 activation, iNOS expression and NO production in macrophages in vitro. WHI-P154 was shown to inhibit other common kinases, including EGFR, Src, Abl, VEGFR, MAPK and PI3-K, and induced apoptosis in human glioblastoma cell lines.WHI-P154 inhibited the adhesion and migration of glioblastoma cells in the ECM. WHI-P154 was significantly cytotoxic to human malignant glioma cell lines U373 and U87, causing apoptotic cell death at micromolar concentrations. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (132.91 mM), Sonication is recommended. |
| Keywords | Janus kinase | WHI-P-154 | WHI-P 154 | ErbB-1 | Apoptosis | inhibit | JAK | WHI-P154 | Epidermal growth factor receptor | HER1 | WHIP154 | Inhibitor | WHI P154 | EGFR |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $9.80/1.8KG |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY